By FieldPulse Staff · March 17, 2026
Tags: strategy, leadership
Conservative groups call MFN drug pricing 'imported socialist price controls,' fracturing Republican support. Novo, J&J, and Pfizer all cite MFN exposure in guidance.
Despite the Trump administration's push to codify most-favored-nation (MFN) drug pricing into law, a coalition of more than 50 conservative and free-market organizations sent a letter to congressional leaders on March 17, 2026 opposing the measure — calling it "imported socialist price controls" that would harm U.S. pharmaceutical innovation. The divide exposes a fault line within the Republican coalition: the White House wants mandatory MFN pricing anchored to reference prices in peer countries like the UK and Germany, while the traditional free-market wing of the party argues the policy woul